

MODIFIED PTO/SB/29 (08/98)

GAU1648/8
+
#7**CONTINUED PROSECUTION APPLICATION (CPA)
REQUEST TRANSMITTAL**Submit an original, and a duplicate for fee processing.
(Only for Continuation or Divisional applications under 37 CFR 1.53(d))

CHECK BOX, If applicable

☐ DUPLICATE

Address to:

Assistant Commissioner for Patents

Box CPA

Washington, DC 20231

Attorney Docket No.
of Prior Application

A-451D

First Named Inventor

Boyle, William J.

Examiner Name

Budens, R.

Group / Art Unit

1648

Express Mail Label No.

EL198793066US

RECEIVED
DEC 18 1998
GROUP 1800

This is a request for a ☒ continuation or ☐ divisional application under 37 CFR 1.53(d), (continued prosecution application (CPA)) of prior application number 09/079,569, filed on May 14, 1998, entitled Antibodies Specific for Osteoprotegerin Binding Proteins and Methods of Use

NOTES

FILING QUALIFICATIONS: The prior application identified above must be a nonprovisional application that is either: (1) complete as defined by 37 CFR 1.51(b), or (2) the national stage of an international application in compliance with 35 U.S.C. 371. A Notice will be placed on a patent issuing from a CPA, except for reissues and designs, to the effect that the patent issued on a CPA and is subject to the twenty-year patent term provisions of 35 U.S.C. 154(a)(2). Therefore, the prior application of a CPA may have been filed before, on or after June 8, 1995.

C-I-P NOT PERMITTED: A continuation-in-part application cannot be filed as a CPA under 37 CFR 1.53(d), but must be filed under 37 CFR 153(b).

EXPRESS ABANDONMENT OF PRIOR APPLICATION: The filing of this CPA is a request to expressly abandon the prior application as of the filing date of the request for a CPA. 37 CFR 1.53(b) must be used to file a continuation, divisional, or continuation-in-part of an application that is not to be abandoned.

ACCESS TO PRIOR APPLICATION: The filing of this CPA will be construed to include a waiver of confidentiality by the applicant under 35 U.S.C. 122 to the extent that any member of the public who is entitled under the provisions of 37 CFR 1.14 to access to, copies of, or information concerning, the prior application may be given similar access to, copies of, or similar information concerning, the other application or applications in the file jacket.

35 U.S.C. 120 STATEMENT: In a CPA no reference to the prior application is needed in the first sentence of the specification and none should be submitted. If a sentence referencing the prior application is submitted, it will not be entered. A request for a CPA is the specific reference required by 35 U.S.C. 120 and to every application assigned the application number identified in such request, 37 CFR 1.78(a).

1. ☐ Enter the unentered amendment previously filed on _____ under 37 CFR 1.116 in the prior nonprovisional application.
2. ☐ A preliminary amendment is enclosed.
3. ☐ This application is filed by fewer than all the inventors named in the prior application, 37 CFR 1.53 (d) (4).
 - a. ☐ **DELETE** the following inventor(s) named in the prior nonprovisional application:

 - b. ☐ The inventor(s) to be deleted are set forth on a separate sheet attached hereto.
4. ☐ A new power of attorney or authorization of agent (PTO/SB/81) is enclosed.
5. ☐ Information Disclosure Statement (IDS) is enclosed:
 - a. ☐ PTO-1449
 - b. ☐ Copies of IDS Citations

12/16/1998
01 FC:131
02 FC:102
03 FC:103

CLAIMS AS FILED

For	Number Filed		Number Extra	Rate	Fee
Total Claims	33	- 20 =	13	x \$22.00 =	\$286.00
Independent Claims	9	- 3 =	6	x \$82.00 =	492.00
MULTIPLE DEPENDENT CLAIMS (if applicable)				+ \$270.00 =	0
Basic Fee				=	\$790.00
Total Filing Fee:					\$1,568.00


6. ☒ Throughout the prosecution of this application, if any extension of time is necessary, please consider this a request therefor.
7. The Commissioner is hereby authorized to credit overpayments or charge the following fees to Deposit Account No. 01-0519 throughout the prosecution of this application:
- a. ☒ Fees required under 37 CFR 1.16.
- b. ☒ Fees required under 37 CFR 1.17.
- c. ☐ Fees required under 37 CFR 1.18.
8. ☐ A check in the amount of \$_____ is enclosed.
9. ☒ New Attorney Docket Number, if desired A-451H
[Prior application Attorney Docket Number will carry over to this CPA unless a new Attorney Docket Number has been provided herein.]
10. a. ☐ Receipt For Facsimile Transmitted CPA (PTO/SB/29A)
- b. ☒ Return Receipt Postcard (Should be specifically itemized. See MPEP 503.)
11. ☒ Other: Supplement IDS and PTO Form 1449 (references attached).....

NOTE: The prior application's correspondence address will carry over to this CPA
UNLESS a new correspondence address is provided below.

12. NEW CORRESPONDENCE ADDRESS

<input type="checkbox"/> Customer Number or Bar Code Label		<input checked="" type="checkbox"/> New correspondence address below			
<div style="border: 1px dashed black; height: 40px; width: 100%;"></div>					
NAME	U.S. Patent Operations/RBW				
	M/S 27-4-A, Department 430				
ADDRESS	AMGEN INC.				
	One Amgen Center Drive				
CITY	Thousand Oaks	STATE	CA	ZIP CODE	91320-1799
COUNTRY	US	TELEPHONE	805-447-2425	FAX	805-499-8011

11. SIGNATURE OF APPLICANT, ATTORNEY OR AGENT REQUIRED

NAME (Print/Type)	ROBERT B. WINTER
SIGNATURE	
REGISTRATION NO. (Attorney/Agent)	34,458
DATE	December 14, 1998